PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242317086 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mithun Ghosh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, The Graduate School, CHA University, Seongnam-si 13488, Republic of Korea. Hauptthemen laut MEDLINE: Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms, Breast Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Poly (ADP-ribose) polymerase (PARP) inhibitors are effective against BRCA1/2-mutated cancers through synthetic lethality. Unfortunately, most cases ultimately develop acquired resistance. Therefore, enhancing PARP inhibitor sensitivity and preventing resistance in those cells are an unmet clinical need. Here, we investigated the ability of paraspeckle component 1 (PSPC1), as an additional synthetic lethal partner with BRCA1/2, to enhance olaparib sensitivity in preclinical models of BRCA1/2-mutated breast and ovarian cancers. In vitro, the combined olaparib and PSPC1 small interfering RNA (siRNA) exhibited synergistic anti-proliferative activity in BRCA1/2-mutated breast and ovarian cancer cells. The combination therapy also demonstrated synergistic tumor inhibition in a xenograft mouse model. Mechanistically, olaparib monotherapy increased the expressions of p-ATM and DNA-PKcs, suggesting the activation of a DNA repair pathway, whereas combining PSPC1 siRNA with olaparib decreased the expressions of p-ATM and DNA-PKcs again. As such, the combination increased the formation of γH2AX foci, indicating stronger DNA double-strand breaks. Subsequently, these DNA-damaged cells escaped G2/M checkpoint activation, as indicated by the suppression of p-cdc25C (Ser216) and p-cdc2 (Tyr15) after combination treatment. Finally, these cells entered mitosis, which induced increased apoptosis. Thus, this proves that PSPC1 inhibition enhances olaparib sensitivity by targeting DNA damage response in our preclinical model. The combination of olaparib and PSPC1 inhibition merits further clinical investigation to enhance PARP inhibitor efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Science, The Graduate School, CHA University, Seongnam-si 13488, Republic of Korea.
- Hematology and Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si 13496, Republic of Korea.
ORCID-Profile: Min Sil Kang, Nar Bahadur Katuwal, Yong Wha Moon
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ghosh, M., Kang, M. S., Katuwal, N. B., Hong, S. D., Jeong, Y. G., Park, S. M., Kim, S. G., & Moon, Y. W. (2023). PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242317086
Vancouver
Ghosh M, Kang MS, Katuwal NB, Hong SD, Jeong YG, Park SM, et al. PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242317086
BibTeX
@article{Ghosh2023,
author = {Ghosh, Mithun and Kang, Min Sil and Katuwal, Nar Bahadur and Hong, Sa Deok and Jeong, Yeong Gyu and Park, Seong Min and Kim, Seul-Gi and Moon, Yong Wha},
title = {PSPC1 Inhibition Synergizes with Poly(ADP-ribose) Polymerase Inhibitors in a Preclinical Model of BRCA-Mutated Breast/Ovarian Cancer},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242317086}
}
EUVIMED